Medication Treatment for Polycystic Ovary Syndrome (PCOS)

Treatment Based on Reproductive Goals

The American College of Physicians recommends combined oral contraceptives (COCs) as first-line therapy for regulating menstrual cycles, providing endometrial protection, and suppressing ovarian androgen secretion in women with PCOS who are not seeking pregnancy 1, 2
COCs increase circulating sex hormone binding globulin and reduce the risk of endometrial cancer in women with PCOS 1
For women with PCOS who wish to conceive, the American Academy of Family Physicians recommends clomiphene citrate as the first-line treatment, with approximately 80% of patients ovulating and half of these conceiving 3
Low-dose gonadotropin therapy is preferred over high-dose therapy for women with PCOS who do not respond to clomiphene 3

A combined approach with antiandrogens and COCs is more effective for hirsutism than either treatment alone, according to the American College of Obstetricians and Gynecologists 1, 2
Commonly used antiandrogens include spironolactone, flutamide, and finasteride, as recommended by the Endocrine Society 1
Topical eflornithine hydrochloride cream is FDA-labeled for hirsutism treatment, though additional benefits in PCOS are unknown, as reported by the American Family Physician 3

The American Diabetes Association recommends that all women with PCOS should be screened for type 2 diabetes with fasting glucose and 2-hour glucose tolerance test 1, 2
Regular screening for dyslipidemia with fasting lipid profile is recommended by the American Heart Association 1, 2
Metformin improves insulin sensitivity, reducing insulin levels and subsequently decreasing ovarian androgen production, as reported by the European Society of Human Reproduction and Embryology 4
Weight loss (even 5% of initial weight) improves metabolic and reproductive abnormalities in PCOS, according to the National Institute of Diabetes and Digestive and Kidney Diseases 1, 4

GLP-1 receptor agonists (liraglutide, semaglutide) show promise for weight management in PCOS, with liraglutide demonstrating superiority to placebo for anthropometric outcomes, as reported by the Obesity Society 5, 6
Semaglutide appears to be the most potent GLP-1 receptor agonist but has limited studies in PCOS, according to the European Association for the Study of Obesity 6